

Claims:

1. An optical imaging contrast agent with affinity for an abnormally expressed biological target associated with endometrioses.
- 5 2. A contrast agent as claimed in claim 1 with molecular weight below 10000 Daltons.
3. A contrast agent as claimed in claim 1 or 2 of formula I
$$V-L-R \quad (I)$$
- 10 wherein V is one or more vector moieties having affinity for an abnormally expressed target in endometriosis, L is a linker moiety or a bond and R is one or more reporter moieties detectable in in vivo optical imaging.
4. A contrast agent as claimed in any of claims 1 to 3 comprising a contrast agent
- 15 substrate, wherein the target is an abnormally expressed enzyme, such that the contrast agent changes pharmacodynamic properties and/or pharmacokinetic properties upon a chemical modification from a contrast agent substrate to a contrast agent product upon a specific enzymatic transformation.
- 20 5. A contrast agent as claimed in any of claims 1 to 4 having affinity for any of the targets selected from angiogenesis targets, adhesion molecules, estrogen receptors, progesterone receptors, Cathepsin H and Cathepsin S, aromatase, reductase, CD10, endoglin, haptoglobin and cyclin D2.
- 25 6. A contrast agent as claimed in claims 3 or 4 wherein V is selected from peptides, peptoid moieties, oligonucleotides, oligosaccharides and lipid-related compounds and traditional organic drug-like small molecules.
7. A contrast agent as claimed in any of claims 3-6 wherein R is a dye that interacts
- 30 with light in the wavelength region from the ultraviolet to the infrared part of the electromagnetic spectrum.
8. A pharmaceutical composition for optical imaging for diagnosis of endometriosis, for follow up of progress of endometriosis, or for follow up of treatment of
- 35 endometriosis, comprising a contrast agent as defined in any of claims 1 to 7 together with at least one pharmaceutically acceptable carrier or excipient.

9. Use of a contrast agent as claimed in any of claims 1 to 7 for the manufacture of a diagnostic agent for use in a method of optical imaging of endometriosis involving administration of said diagnostic agent to an animate subject and generation of an image of at least part of said subject.

5

10. A method of generating an optical image of an animate subject involving administering a contrast agent to said subject and generating an optical image of at least a part of said subject to which said contrast agent has distributed, characterized in that as said contrast agent is used a contrast agent as defined in any of claims 1 to 7.

10

11. Method as claimed in claim 10 for diagnosis of endometriosis, for follow up the progress of endometriosis development or for follow up treatment of endometriosis using a contrast agent as defined in any of claims 1 to 7.

15

12. Use of a contrast agent as defined in any of claims 1 to 7 for optical imaging of endometriosis.